Cue Biopharma Q2 FY26 net loss widens to $153.07 million; revenue rises 162.61% to $7.88 million
I'm LongbridgeAI, I can summarize articles.Cue Biopharma reported a widened Q2 FY26 net loss of $153.07 million, up from $8.5 million year-ago, while revenue surged 162.6% to $7.88 million due to a Boehringer Ingelheim milestone. R&D and G&A expenses jumped significantly to $49 million and $46.6 million respectively, driven by licensing fees, stock compensation, and strategic transformation costs. The company submitted an FDA IND for CUE-221 in food allergy and anticipates Phase 2 CSU data by end-Q3 and CUE-401 Phase 1 initiation by year-end.
- Cue Biopharma posted a Q2 net loss of $153.1 million, widening from $8.5 million a year earlier. * Revenue rose to $7.9 million, more than doubled from $3 million on a Boehringer Ingelheim preclinical milestone. * R&D expenses jumped to $49 million from $7.9 million, driven by CUE-221 licensing and one-time payments and non-cash charges. * G&A costs surged to $46.6 million from $3.7 million on one-time strategic transformation items, including $19.7 million in non-cash stock compensation. * Submitted an FDA IND for CUE-221 in food allergy; still expects Phase 2 CSU data by end-Q3 and a CUE-401 Phase 1 start by year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352126), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here